Anti PD-1 Neo-adjuvant Treatment for NSCLC

NCT02938624 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

OTHER_GOV

Sponsor class

Conditions

Non Small Cell Lung Carcinoma
Stage I
Stage II

Interventions

DRUG: Pembrolizumab 200 mg IV single dose
DRUG: Pembrolizumab 200 mg IV twice interval 21 days
DRUG: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
DRUG: Pembrolizumab 100 mg I.V single dose
PROCEDURE: Surgical resection of tumor

Sponsor

Jair Bar, M.D., Ph.D.

Collaborators

[object Object]